Possible treatment of Parkinson's disease with intrathecal medication in the MPTP model.
Hood
T W
TW
Department of Surgery, University of Michigan Medical School, Ann Arbor 48109.
Domino
E F
EF
Greenberg
H S
HS
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D015102:3,4-Dihydroxyphenylacetic Acid / Q000134:cerebrospinal fluid; D000818:Animals; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D007260:Infusion Pumps; D007278:Injections, Spinal; D007980:Levodopa / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000134:cerebrospinal fluid / Q000627:therapeutic use; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D011725:Pyridines; D013997:Time Factors
D011725:Pyridines; D015102:3,4-Dihydroxyphenylacetic Acid; D007980:Levodopa; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; C035420:levodopa methyl ester; D006719:Homovanillic Acid